After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ABUS falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Arbutus Biopharma Corp is $642.38M. A total of 1.09 million shares were traded on the day, compared to an average of 841.01K shares.
Insider Activity
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, ABUS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, HASTINGS DAVID C sold 22,183 shares of ABUS for 3.28 per share on Feb 04 ’25. After the transaction, the Chief Financial Officer now owns 159,724 company shares. In a previous transaction on Feb 04 ’25, Sims Karen sold 19,348 shares at 3.28 per share. ABUS shares that Chief Medical Officer owns now total 106,194.
Among the insiders who sold shares, McElhaugh Michael J. disposed of 23,790 shares on Feb 04 ’25 at a per-share price of $3.28. This resulted in the Interim President & CEO holding 1,481,003 shares of ABUS after the transaction. In another insider transaction, Naftzger J. Christopher sold 11,333 shares at $3.28 per share on Feb 04 ’25. Company shares held by the General Counsel and CCO now total 86,244.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for ABUS in the last 3 months, the mean price target is $5.25 with high estimates of $7.00 and low estimates of $4.00. In terms of 52-week highs and lows, ABUS has a high of $4.72 and a low of $2.30.
As of this writing, ABUS has an earnings estimate of -$0.12 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.13.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.56, while its Total Shareholder’s Equity was $169.44M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 4.50.
